Literature DB >> 8223850

Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin.

H Zaghouani1, Y Kuzu, H Kuzu, T D Brumeanu, W J Swiggard, R M Steinman, C A Bona.   

Abstract

Major histocompatibility complex (MHC) class I and II products are specialized to present antigens via different intracellular processing routes. Peptides originating from proteins in the cytoplasm can gain access to class I peptide-binding grooves, most likely in the rough endoplasmic reticulum. Peptides from proteins in acidic endocytic vacuoles gain access to class II. It has been proposed that MHC class I products also can capture peptides from "exogenous" or noninfectious sources, and this assumption underlies the use of intact proteins as vaccines for CD8+ cytotoxic T lymphocytes. Here we describe quantitative information comparing the efficacy of peptide presentation from exogenous proteins by administering a class I- and II-restricted peptide within the same context, the CDR3 loop of the VH domain of a self immunoglobulin. Antigen-presenting cells (APC), including primary dendritic cells, efficiently present an influenza hemagglutinin peptide from the immunoglobulin (Ig) carrier (50% maximal response at 10 nM Ig-HA) to an MHC class II-restricted T cell. In contrast, these same APC are unable to present an influenza nucleoprotein (NP) peptide from the same context (1 microM Ig-NP) to an MHC class I-restricted T cell. Ig-NP DNA transfectants do present the nucleoprotein viral peptide on class I. Thus, peptides within the complementarity-determining region loops of Ig carriers can be presented on class I or II MHC products, but the endocytic compartment, when offered MHC class I- and II-restricted peptides within the same carrier protein context, favors presentation by class II by at least 1000-fold.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223850     DOI: 10.1002/eji.1830231104

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis.

Authors:  K Manoutcharian; L I Terrazas; G Gevorkian; G Acero; P Petrossian; M Rodriguez; T Govezensky
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Infection-triggered regulatory mechanisms override the role of STAT 4 in control of the immune response to influenza virus antigens.

Authors:  A Bot; E Rodrigo; T Wolfe; S Bot; M G Von Herrath
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  B and T cell responses elicited by monoclonal anti-idiotypic antibody (Ab2beta) mimicking gp43 from Paracoccidioides brasiliensis.

Authors:  E B Souza; J D Lopes; S R Almeida
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

4.  Antibodies designed as effective cancer vaccines.

Authors:  R L Metheringham; V A Pudney; B Gunn; M Towey; I Spendlove; L G Durrant
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

5.  Antiviral protective immunity induced by major histocompatibility complex class I molecule-restricted viral T-lymphocyte epitopes inserted in various positions in immunologically self and nonself proteins.

Authors:  G Weidt; W Deppert; S Buchhop; H Dralle; F Lehmann-Grube
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

6.  Dendritic cells transfected with scFv from Mab 7.B12 mimicking original antigen gp43 induces protection against experimental Paracoccidioidomycosis.

Authors:  Karen S Ferreira; Andrea Q Maranhão; Maria C C Garcia; Marcelo M Brígido; Suelen S Santos; José D Lopes; Sandro R Almeida
Journal:  PLoS One       Date:  2011-01-07       Impact factor: 3.240

7.  Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergy.

Authors:  B Min; K L Legge; C Pack; H Zaghouani
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

Review 8.  New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection.

Authors:  Volker Schirrmacher
Journal:  Biomedicines       Date:  2020-03-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.